Introduction

Background: Approximately 10% of all hepatitis C virus infections in the United States result from genotype 3 infection. Accordingly, less extensive clinical trial data exists for genotype 3 than with genotype 1. Patients with HCV genotype 3, when compared with HCV non-3 genotypes, have relatively faster rates of fibrosis progression, higher prevalence of severe (Grade 3) steatosis, and a higher incidence of hepatocellular carcinoma. In the current direct-acting antiviral therapy era, patients with genotype 3 infection have been relatively difficult to treat compared with other genotypes, especially in patients with cirrhosis. Recent data with sofosbuvir-velpatasvir are very encouraging, with SVR rates of 97% in treatment-naive patients and 90% in treatment-experienced patients. The cost of recommended therapy for genotype 3 infection ranges from $74,760 to $295,000 (Figure 1). The following discussion regarding initial treatment and retreatment of patients with genotype 3 chronic hepatitis C assumes the patient and their clinician have already made the decision to initiate hepatitis C therapy.

Medications used to Treat Hepatitis C: The HCV Medications section on this web site provides detailed information for each of the FDA-approved medications listed in the treatment recommendations, including links to the full prescribing information and to patient assistance programs. Adherence with the treatment regimen is of paramount importance. Thus, patients should receive detailed counseling regarding the importance of adherence prior to starting therapy, as well as intensive monitoring and follow-up during therapy.
Genotype 3: Initial Treatment

Background: Clinical trials involving patients with genotype 2 or 3 infection have examined the efficacy of sofosbuvir plus weight-based ribavirin given for 12 to 16 weeks and have reported substantially lower SVR rates (30 to 60%) in patients with genotype 3 than with genotype 2 infection. The relatively lower SVR rates with genotype 3 were improved by using a 12-week course of sofosbuvir plus ribavirin plus peginterferon, or extending the all-oral sofosbuvir plus ribavirin regimen to 24 weeks. The dual DAA combination of daclatasvir plus sofosbuvir proved more efficacious than sofosbuvir plus ribavirin combination, but required a longer duration (16 or 24 weeks) in cirrhotic genotype 3 patients; the role of ribavirin remained unclear when duration was extended. Most recently, velpatasvir-sofosbuvir has demonstrated excellent SVR rates in treatment-naive genotype 3 patients, including those with compensated cirrhosis.

Factors to Consider Prior to Choosing Initial Treatment Regimen: For patients chronically infected with genotype 3 hepatitis C, three factors should be considered when choosing the initial treatment regimen and duration: baseline NS5A resistance (for naive cirrhotics or treatment-experienced non-cirrhotics, presence or absence of cirrhosis, and cost. The management of genotype 3 patients with decompensated cirrhosis, renal impairment, HIV coinfection, acute hepatitis C infection, or post-liver transplantation is not addressed in this lesson.

AASLD/IDSA Guidance (see Initial Treatment of HCV Infection): The following is a summary of joint recommendations issued by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). The recommendations listed below are for patients with hepatitis C genotype 3 infection who are treatment naive.

Table 1. Genotype 3: Initial Treatment
Treatment-Naive Patients

Recommended regimens are listed in groups by level of evidence, then alphabetically.

Recommended for Genotype 3 patients without Cirrhosis

**Daclatasvir**

<table>
<thead>
<tr>
<th>60 mg* once daily</th>
<th>for 12 weeks</th>
</tr>
</thead>
</table>

**Sofosbuvir**

<table>
<thead>
<tr>
<th>400 mg once daily</th>
<th>for 12 weeks</th>
</tr>
</thead>
</table>

Rating: Class I, Level A

Note: *The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. See the daclatasvir prescribing information for details.

Recommended for Genotype 3 patients without Cirrhosis

**Sofosbuvir-VELpatasvir**

Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) one tablet once daily for 12 weeks

Rating: Class I, Level A

Recommended
Recommended for Genotype 3 patients with Compensated Cirrhosis

**Sofosbuvir-Velpatasvir**

Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) one tablet once daily for 12 weeks

± **Ribavirin**

1000 mg if <75 kg or 1200 mg if ≥75 kg for 12 weeks

RAV testing for Y93H is recommended for cirrhotic patients and ribavirin should be included in the regimen if the Y93H is present.

Rating: **Class I, Level A**

---

Recommended for Genotype 3 patients with Compensated Cirrhosis

**Daclatasvir**

60 mg* once daily for 24 weeks

± **Sofosbuvir**

400 mg once daily for 24 weeks

± **Ribavirin**

1000 mg if <75 kg or 1200 mg if ≥75 kg for 24 weeks

RAV testing for Y93H is recommended for cirrhotic patients and ribavirin should be included in the regimen if the Y93H is present.

Rating: **Class IIa, Level B**

Note: (i) *The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively; see the daclatasvir prescribing information for details. (ii) The ribavirin daily dose is given in two divided doses.

---


---

**Key Studies to Support Recommendations:** The following key studies support the recommendations for treatment of patients with chronic hepatitis C and genotype 3 infection who are treatment naive or who have previously received treatment and had virologic relapse with a regimen that included peginterferon and ribavirin. Click on the study name (blue) to see more details and to view a PowerPoint slide summary.

- **ALLY-3:** The phase 3 ALLY-3 trial enrolled 152 patients with genotype 3 infection (101 treatment-naive and 51 treatment experienced). All patients received a 12-week course of the oral regimen of daclatasvir (60 mg once daily) plus sofosbuvir (400 mg once daily). Patients with compensated cirrhosis were allowed in the trial. Overall, SVR12 was achieved in 84 (89%) of 94 of the treatment-naive patients (97% in those without cirrhosis and 58% on those with cirrhosis).
- **ASTRAL-3:** The ASTRAL-3 trial was a randomized, open-label phase 3 study that compared sofosbuvir-velpatasvir for 12 weeks with sofosbuvir plus ribavirin for 24 weeks in patients with genotype 3 HCV infection. Of the 552 patients enrolled in the study, 30% had compensated cirrhosis and 26% were treatment-experienced. For the treatment-naive patients who received velpatasvir-sofosbuvir 200 (97%) of 206 patients achieved an SVR 12, which was significantly better than the 83% SVR12 rate in patients treated with sofosbuvir plus ribavirin.
- **BOSON:** In the randomized, open-label BOSON trial, investigators enrolled treatment-naive and treatment-experienced patients with genotype 2 or 3 chronic HCV infection, with or
without cirrhosis, to receive one of three treatment regimens: sofosbuvir plus ribavirin for 16 weeks, sofosbuvir plus ribavirin for 24 weeks, and sofosbuvir plus ribavirin plus peginterferon alfa-2a for 12 weeks. Among the 592 patients enrolled in the study, 92% had genotype 3 infection. For the treatment-naive patients with genotype 3 infection, the SVR 12 rates were 77% with the 16-week sofosbuvir plus ribavirin regimen, 88% with 24 weeks of sofosbuvir plus ribavirin, and 95% with 12 weeks of sofosbuvir plus ribavirin plus peginterferon. For the treatment-naive patients with genotype 3 infection, the superiority of the results with the 12-week regimen of sofosbuvir plus ribavirin plus peginterferon was maintained in patients with or without cirrhosis.

- **VALENCE**: This phase 3 trial examined the efficacy of sofosbuvir and ribavirin in treatment-naive and treatment-experienced patients with genotype 2 or 3. After very poor results were observed using a 12-week course for patients with genotype 3, the protocol was modified so that patients with genotype 3 received 24 weeks of therapy. Among the treatment-naive patients with genotype 3 who received a 24-week treatment course of therapy, 99 (94%) of 105 achieved an SVR12; presence of cirrhosis did not significantly impact results for the treatment-naive genotype 3 patients with the 24-week treatment course.

- **FISSION**: This phase 3 trial enrolled 499 treatment-naive patients with genotype 2 or 3 HCV infection and randomized treatment to 12 weeks of sofosbuvir plus ribavirin versus 24 weeks of peginterferon plus ribavirin. For patients with genotype 3 infection, 102 (56%) of 183 achieved an SVR12 with sofosbuvir plus ribavirin, compared with 110 (63%) of 176 of those treated with peginterferon plus ribavirin. The results with a 12-week course of sofosbuvir plus ribavirin in genotype 3 patients were disappointing when compared with those observed in patients with genotype 2 infection.

- **POSITRON**: This phase 3 trial enrolled patients with genotype 2 or 3 infection who were (a) not willing to receive interferon, (b) not able to receive interferon, or (c) were intolerant to a previous course of interferon. A total of 278 patients were randomized to receive a 12-week course of sofosbuvir plus ribavirin versus placebo. For patients with genotype 3 infection, 60 (61%) of 98 achieved an SVR12 with sofosbuvir plus ribavirin. With this 12-week treatment course, cirrhosis appeared to greatly impact the SVR12 response rates: 3 (21%) of 14 patients with cirrhosis obtained an SVR12 compared with 57 (68%) of 84 of those without cirrhosis.

- **PROTON**: In this two cohort phase 2 trial, which enrolled treatment-naive patients with genotypes 1, 2, or 3 and no evidence of cirrhosis, a total of 25 patients in cohort B with genotype 2 (n =15) or genotype 3 (n =10) received a 12-week course of sofosbuvir, ribavirin, and peginterferon. Overall, 23 (92%) of the 25 patients with genotype 2 or 3 met criteria for SVR24; the results were not broken down by genotype 3 versus genotype 2. Of the two patients who failed to meet the SVR24 endpoint, one was lost to follow-up after a baseline visit, and the other had an undetectable HCV RNA level using a commercial assay that had a higher cutoff value of 43 IU/mL.

- **ELECTRON: Arms 1-8**: The ELECTRON study is a complex 22-arm study. This phase 2a component of the ELECTRON study enrolled patients with genotypes 1 to 3 into one of 8 treatment arms. Six of the treatment arms involved treatment-naive patients with genotype 2 or 3 infection who received sofosbuvir monotherapy for 12 weeks, sofosbuvir plus ribavirin for 12 weeks, or sofosbuvir (12 weeks) plus ribavirin (8 to 12 weeks) plus peginterferon (4 to 12 weeks). Forty (70%) of the 60 patients enrolled with genotype 2 or 3 infection had genotype 3 infection. Excluding the sofosbuvir monotherapy arm (which did not perform well), the remaining 50 (100%) of 50 patients with genotype 2 or 3 achieved an SVR24.
Genotype 3: Retreating Persons who Failed Prior Therapy

**Background:** Genotype 3 infection has emerged as the most challenging of all HCV genotypes to treat in this interferon-free era, particularly in patients with prior treatment failure and cirrhosis. In treatment-experienced genotype 3 patients, clinical experience combined with limited data from clinical trials to date have suggested the regimen of sofosbuvir plus ribavirin may be suboptimal, with an estimated response rate of 80% among cirrhotics with the 24-week regimen. There are now several options for retreatment of patients with genotype 3 infection who failed either prior peginterferon plus ribavirin regimen or prior sofosbuvir-based therapy.

**Factors to Consider Prior to Choosing Retreatment Regimen:** For retreatment of patients with genotype 3 hepatitis C, several factors influence the regimen choice, including the prior regimen failed, presence or absence of cirrhosis, and medication cost. The retreatment of genotype 3 patients with decompensated cirrhosis, renal impairment, acute hepatitis C infection, or post-liver transplantation is not addressed in this lesson.

**AASLD/IDSA Guidance** (see [Retreatment of Persons in Whom Prior Therapy has Failed](#)): The following is a summary of joint recommendations issued by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). The recommendations listed below are for patients with hepatitis C genotype 3 infection who are treatment experienced and failed prior therapy with either (1) peginterferon plus ribavirin or (2) sofosbuvir plus ribavirin.

**Table 2. Genotype 3: Retreatment Peginterferon plus Ribavirin Treatment-Experienced Patients**

Recommended regimens are listed in groups by level of evidence, then alphabetically.

**Recommended for Retreatment of Genotype 3 patients without Cirrhosis**

**Daclatasvir**
60 mg* once daily for 12 weeks

**Sofosbuvir**
400 mg once daily for 12 weeks

RAV testing for Y93H is recommended and ribavirin should be included in regimen if present.
Rating: Class I, Level A
Note: *The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A4 inducers and inhibitors, respectively. See the daclatasvir prescribing information for detailed information.

**Recommended for Retreatment of Genotype 3 patients without Cirrhosis**

**Sofosbuvir-Velpatasvir**
Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) one tablet once daily for 12 weeks

RAV testing for Y93H is recommended and ribavirin should be included in regimen if present.
Rating: Class I, Level A
Recommended for Retreatment of Genotype 3 patients with Compensated Cirrhosis

**Sofosbuvir-Velpatasvir**
*Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) one tablet once daily for 12 weeks*

**Ribavirin**
- 1000 mg if <75 kg
- 1200 mg if ≥75 kg for 12 weeks

Rating: **Class I, Level B**

Note: The ribavirin daily dose is given in two divided doses.

Recommended for Retreatment of Genotype 3 patients with Compensated Cirrhosis

**Daclatasvir**
- 60 mg* once daily for 24 weeks

**Sofosbuvir**
- 400 mg once daily for 24 weeks

**Ribavirin**
- 1000 mg if <75 kg
- 1200 mg if ≥75 kg for 24 weeks

Rating: **Class IIa, Level B**

Note: (i) *the dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. See the daclatasvir prescribing information for details; (ii) the ribavirin daily dose is given in two divided doses.

Recommended


**Table 3. Genotype 3: Retreatment**

**Sofosbuvir plus Ribavirin Treatment-Experienced Patients**

Recommended regimens are listed in groups by level of evidence, then alphabetically.

**Recommended for Genotype 3 patients, regardless of cirrhosis status**

**Daclatasvir**
- 60 mg* once daily for 24 weeks

**Sofosbuvir**
- 400 mg once daily for 24 weeks

**Ribavirin**
- 1000 mg if <75 kg
- 1200 mg if ≥75 kg x 24 weeks

Rating: **Class IIa, Level C**

Note: *The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. See the daclatasvir prescribing information for details; the ribavirin daily dose is given in two divided doses.

**Recommended for Genotype 3 patients, regardless of cirrhosis status**

**Sofosbuvir-Velpatasvir**
*Fixed-dose combination of*

**Ribavirin**
- 1000 mg if <75 kg
- 1200 mg if ≥75 kg for 12 weeks
sofosbuvir (400 mg)/velpatasvir (100 mg) one tablet once daily for 12 weeks

Rating: Class IIa, Level C

Note: The ribavirin daily dose is given in two divided doses.

Source: AASLD-IDSA. Recommendations for testing, management, and treating hepatitis C. Retreatment of persons in whom prior therapy has failed: DAA-experienced (including NS5A inhibitors), genotype 3 patients with or without compensated cirrhosis. [AASLD-IDSA Hepatitis C Guidance] - Accessed March 10, 2017.

Key Studies to Support Recommendations: The following key studies support the recommendations for treatment of patients with chronic hepatitis C and genotype 3 infection who are treatment experienced and were considered a nonresponder (partial responder or null responder). Click on the study name (blue) to see more details and to view a PowerPoint slide summary.

- **ALLY-3**: The phase 3 ALLY-3 trial enrolled 152 patients with genotype 3 infection (101 treatment-naive and 51 treatment experienced). All patients received a 12-week course of the oral regimen of daclatasvir (60 mg once daily) plus sofosbuvir (400 mg once daily). Patients with compensated cirrhosis were allowed in the trial. Overall, SVR12 was achieved in 41 (87%) of 47 of the treatment-experienced patients (94% in those without cirrhosis and 69% on those with cirrhosis).

- **ASTRAL-3**: The ASTRAL-3 trial was a randomized, open-label phase 3 study that compared sofosbuvir-velpatasvir for 12 weeks with sofosbuvir plus ribavirin for 24 weeks in patients with genotype 3 HCV infection. Of the 552 patients enrolled in the study, 26% were treatment-experienced. For the treatment-experienced patients who received velpatasvir-sofosbuvir 64 (90%) of 71 patients achieved an SVR 12, which was significantly better than the 64% SVR12 rate observed in the treatment-experienced patients who received sofosbuvir plus ribavirin.

- **BOSON**: The randomized, open-label BOSON trial, investigators enrolled treatment-naive and treatment-experienced patients with genotype 2 or 3 chronic HCV infection, with or without cirrhosis, to receive one of three treatment regimens: sofosbuvir plus ribavirin for 16 weeks, sofosbuvir plus ribavirin for 24 weeks, and sofosbuvir plus ribavirin plus peginterferon alfalfa for 12 weeks. Among the 592 patients enrolled in the study, 92% had genotype 3 infection. For the treatment-experienced patients with genotype 3 infection, the SVR 12 rates were 64% with the 16-week sofosbuvir plus ribavirin regimen, 80% with 24 weeks of sofosbuvir plus ribavirin, and 91% with 12 weeks of sofosbuvir plus ribavirin plus peginterferon. For the treatment-experienced patients with genotype 3 infection, the superiority of the results with the 12-week regimen of sofosbuvir plus ribavirin plus peginterferon was maintained in patients with or without cirrhosis.

- **FUSION**: This phase 3 trial compared a 12 week and 16 week course of sofosbuvir plus ribavirin in treatment-experienced patients with genotype 2 or 3 HCV infection. For patients with genotype 3 infection, only 19 (30%) of 64 achieved an SVR12 with the 12-week course compared with 39 (62%) of 63 in the 16-week course. Of note, for the 47 patients with genotype 3 and cirrhosis, the SVR12 rates were significantly higher with a 16-week course (61%) than with a 12-week course (19%). This study clearly established that a 12 or 16-week course of sofosbuvir plus ribavirin is suboptimal for treatment-experienced patients with genotype 3 infection.

- **VALENCE**: In this phase 3 trial, investigators enrolled treatment-naive and treatment-
experienced patients with genotype 2 or 3 HCV infection. Among the 419 total patients enrolled, 250 had genotype 3 and they received a 24-week course of sofosbuvir plus ribavirin or placebo. For the treatment-experienced patients with genotype 3 infection, 114 (79%) of 145 achieved an SVR12. Among these treatment-experienced patients, SVR12 was obtained in 29 (62%) of 47 with cirrhosis compared with 85 (87%) of 98 without cirrhosis.

- **LONESTAR-2**: In this phase 2 trial, treatment-experienced patients with genotype 2 or 3 infection received a 12-week course of open label sofosbuvir plus peginterferon plus ribavirin. Among the treatment-experienced patients with genotype 3 infection, 20 (83%) of 24 achieved an SVR12. Of note, more than 50% of the patients in this study had cirrhosis and 10 (83%) of 12 patients with genotype 3 infection and cirrhosis obtained an SVR12.
Genotype 3: Treatment Regimens under Study

Treatment Regimens under Study for Patients with HCV Genotype 3: The following list includes several treatment regimens under study that are not currently recommended in the AASLD/IDSA guidance.

- **Ledipasvir-Sofosbuvir**: In the ELECTRON-2 trial, 51 treatment-naive patients with genotype 3 HCV were randomized to receive ledipasvir-sofosbuvir (n = 25) or ledipasvir-sofosbuvir plus ribavirin (n = 25). The study included patients with cirrhosis, but only 15% of the genotype 3 patients had cirrhosis. In the treatment arm that included ribavirin, 25 (100%) achieved an SVR12, compared with 16 (64%) in the arm without ribavirin. In a separate study, investigators used a 12-week course of ledipasvir-sofosbuvir plus ribavirin for 50 treatment-experienced patients with genotype 3 HCV, including those with cirrhosis. Overall, SVR12 was achieved in 82% of the patients, including 89% in those without cirrhosis and 73% in those with cirrhosis. Although these data suggest some efficacy with this regimen, its comparability relative to the standard of care is not established and neither the FDA nor AASLD have approved its use for genotype 3 patients.

- **Paritaprevir-Ritonavir plus ABT-530 and Ribavirin**: This phase 2, open-label trial examined a 12-week course of the paritaprevir-ritonavir plus the investigational pangenotypic NS5A inhibitor ABT-530, with ribavirin in 10 treatment-naive, non-cirrhotic patients with genotype 3a infection. Nine (90%) of the 10 patients achieved an SVR at post-treatment weeks 12 and 24.

- **Voxilaprevir (formerly GS-9857) plus Sofosbuvir plus Velpatasvir**: The regimen of the investigational NS3/4a protease inhibitor, voxilaprevir, in combination with sofosbuvir and velpatasvir has been shown in phase 2 trial to have excellent SVR rates in treatment-naive and treatment-experienced patients with HCV genotype 1-6.

- **ABT-493 and ABT-530**: A next-generation NS3/4A protease inhibitor, ABT-493, which is distinctive in its pangenotypic activity is also being evaluated with ABT-530 in patients with genotype 2 or 3 infection.
Summary Points

- In the new direct-acting antiviral treatment era, genotype 3 has emerged as the most difficult genotype to treat.
- For treatment-naive patients without cirrhosis, two regimens are recommended with equal rating: (1) daclatasvir plus sofosbuvir for 12 weeks, or (2) sofosbuvir-velpatasvir for 12 weeks.
- For treatment-naive patients with compensated cirrhosis, two regimens are recommended: (1) sofosbuvir-velpatasvir for 12 weeks, or (2) daclatasvir plus sofosbuvir, with or without ribavirin for 24 weeks. Baseline NS5A genotype 3 resistance testing should be performed, and ribavirin should be added to sofosbuvir-velpatasvir or sofosbuvir plus daclatasvir if the Y93H mutation is detected. The sofosbuvir-velpatasvir has a higher rating and is much less expensive.
- For treatment-experienced patients without cirrhosis, two regimens are recommended with equal rating: (1) daclatasvir plus sofosbuvir for 12 weeks, or (2) sofosbuvir-velpatasvir for 12 weeks. Baseline NS5A genotype 3 resistance testing should be performed, and ribavirin should be added to daclatasvir plus sofosbuvir or sofosbuvir-velpatasvir if the Y93H mutation is detected.
- For treatment-experienced patients with compensated cirrhosis, two regimens are recommended: (1) sofosbuvir-velpatasvir plus ribavirin for 12 weeks, or (2) daclatasvir plus sofosbuvir plus ribavirin for 24 weeks. The sofosbuvir-velpatasvir plus ribavirin has a higher rating and is much less expensive than daclatasvir plus sofosbuvir plus ribavirin.
- The recommended regimen for genotype 3 treatment-experienced patients who have failed prior treatment with sofosbuvir consists of (1) daclatasvir plus sofosbuvir plus ribavirin for 24 weeks, or (2) sofosbuvir-velpatasvir plus ribavirin for 12 weeks.
- For treatment-naïve patients with compensated cirrhosis and treatment-experienced non-cirrhotic patients, baseline NS5A genotype 3 resistance testing should be performed, and ribavirin added to sofosbuvir-velpatasvir or sofosbuvir plus daclatasvir if the Y93H mutation is detected.
- Regimens under study for genotype 3 include (a) ledipasvir-sofosbuvir, (b) paritaprevir-ritonavir plus the investigational NS5A inhibitor ABT-530, and (c) the combination of ABT-530 and ABT-493.
Citations


9. AASLD-IDSA. Recommendations for testing, management, and treating hepatitis C. Treatment-Naive Genotype 3. [AASLD-IDSA Hepatitis C Guidance] -

10. AASLD-IDSA. Recommendations for testing, management, and treating hepatitis C. Treatment-Experienced Genotype 3. [AASLD-IDSA Hepatitis C Guidance] -


25. AASLD-IDSA. Recommendations for testing, management, and treating hepatitis C. Initial treatment of HCV infection: treatment-naive genotype 3 without cirrhosis.
   [AASLD-IDSA Hepatitis C Guidance]

26. AASLD-IDSA. Recommendations for testing, management, and treating hepatitis C. Initial treatment of HCV infection: treatment-naive genotype 3 with compensated cirrhosis
   [AASLD-IDSA Hepatitis C Guidance]

   [PubMed Abstract]

28. AASLD-IDSA. Recommendations for testing, management, and treating hepatitis C. Retreatment of persons in whom prior therapy has failed: peginterferon/ribavirin-experienced, genotype 3 patients with compensated cirrhosis.
   [AASLD-IDSA Hepatitis C Guidance]

29. AASLD-IDSA. Recommendations for testing, management, and treating hepatitis C. Retreatment of persons in whom prior therapy has failed: peginterferon/ribavirin-experienced, genotype 3 patients without cirrhosis.
   [AASLD-IDSA Hepatitis C Guidance]

30. AASLD-IDSA. Recommendations for testing, management, and treating hepatitis C. Retreatment of persons in whom prior therapy has failed: DAA-experienced (including NS5A inhibitors), genotype 3 patients with or without compensated cirrhosis.
   [AASLD-IDSA Hepatitis C Guidance]

   [PubMed Abstract]

32. Lawitz E, Buti M, Vierling JM, et al. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017;2:814-823.
   [PubMed Abstract]

   [PubMed Abstract]

**References**

  [PubMed Abstract]


[PubMed Abstract] -
Figures

Figure 1 Cost of Medication Regimens used to Treat Genotype 3 Chronic HCV

This figure shows the approximate cost of different regimens used for treatment-naive and/or treatment-experienced patients with genotype 3 chronic HCV. Cost based on available wholesale acquisition price data and estimates shown for patients without cirrhosis and with compensated cirrhosis.

<table>
<thead>
<tr>
<th>Regimen and Duration of Therapy</th>
<th>Cost of Regimen*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GT 3 HCV without Cirrhosis</strong></td>
<td></td>
</tr>
<tr>
<td>Daclatasvir + Sofosbuvir x 12 weeks</td>
<td>$147,000</td>
</tr>
<tr>
<td>Sofosbuvir-Velpatasvir x 12 weeks</td>
<td>$74,760</td>
</tr>
<tr>
<td><strong>GT 3 HCV with Compensated Cirrhosis</strong></td>
<td></td>
</tr>
<tr>
<td>Sofosbuvir-Velpatasvir x 12 weeks +/- Ribavirin</td>
<td>$74,760</td>
</tr>
<tr>
<td>Daclatasvir + Sofosbuvir x 24 weeks +/- Ribavirin</td>
<td>$294,000</td>
</tr>
</tbody>
</table>

*Cost estimates based on Wholesale Acquisition Cost (WAC)
Table 1. Genotype 3: Initial Treatment
Treatment-Naive Patients

Recommended regimens are listed in groups by level of evidence, then alphabetically.

**Recommended for Genotype 3 patients without Cirrhosis**

**Daclatasvir** + **Sofosbuvir**
60 mg* once daily for 12 weeks + 400 mg once daily for 12 weeks

Rating: **Class I, Level A**

Note: *The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. See the daclatasvir prescribing information for details.

**Recommended for Genotype 3 patients without Cirrhosis**

**Sofosbuvir-Velpatasvir**
Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) one tablet once daily for 12 weeks

Rating: **Class I, Level A**

**Recommended for Genotype 3 patients with Compensated Cirrhosis**

**Sofosbuvir-Velpatasvir ± Ribavirin**
Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) one tablet once daily for 12 weeks ± 1000 mg if <75 kg or 1200 mg if ≥75 kg for 12 weeks

RAV testing for Y93H is recommended for cirrhotic patients and ribavirin should be included in the regimen if the Y93H is present.
Rating: **Class I, Level A**

**Recommended for Genotype 3 patients with Compensated Cirrhosis**

**Daclatasvir** + **Sofosbuvir ± Ribavirin**
60 mg* once daily for 24 weeks + 400 mg once daily for 24 weeks ± 1000 mg if <75 kg or 1200 mg if ≥75 kg for 24 weeks

RAV testing for Y93H is recommended for cirrhotic patients and ribavirin should be included in the regimen if the Y93H is present.
Rating: **Class IIa, Level B**

Note: (i) *The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively; see the daclatasvir prescribing information for details.
information for details. (ii) The ribavirin daily dose is given in two divided doses.

Table 2. Genotype 3: Retreatment
Peginterferon plus Ribavirin Treatment-Experienced Patients

Recommended regimens are listed in groups by level of evidence, then alphabetically.

Recommended for Retreatment of Genotype 3 patients without Cirrhosis

**Daclatasvir**
60 mg* once daily for 12 weeks

**Sofosbuvir**
400 mg once daily for 12 weeks

RAV testing for Y93H is recommended and ribavirin should be included in regimen if present.
Rating: Class I, Level A
Note: *The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. See the daclatasvir prescribing information for detailed information.

Recommended for Retreatment of Genotype 3 patients without Cirrhosis

**Sofosbuvir-Velpatasvir**
Fixed-dose combination of
sofosbuvir (400 mg)/velpatasvir (100 mg) one tablet once daily for 12 weeks

RAV testing for Y93H is recommended and ribavirin should be included in regimen if present.
Rating: Class I, Level A

Recommended for Retreatment of Genotype 3 patients with Compensated Cirrhosis

**Sofosbuvir-Velpatasvir**
Fixed-dose combination of
sofosbuvir (400 mg)/velpatasvir (100 mg) one tablet once daily for 12 weeks

**Ribavirin**
1000 mg if <75 kg
or 1200 mg if ≥75 kg for 12 weeks

Rating: Class I, Level B
Note: The ribavirin daily dose is given in two divided doses.

Recommended for Retreatment of Genotype 3 patients with Compensated Cirrhosis

**Daclatasvir**
60 mg* once daily for 24 weeks

**Sofosbuvir**
400 mg once daily for 24 weeks

**Ribavirin**
1000 mg if <75 kg
or 1200 mg if ≥75 kg for 24 weeks

Rating: Class IIa, Level B
Note: (i) *The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. See the daclatasvir prescribing information for detailed information.
information for details; (ii) the ribavirin daily dose is given in two divided doses.

**Recommended**

### Table 3. Genotype 3: Retreatment
**Sofosbuvir plus Ribavirin Treatment-Experienced Patients**

Recommended regimens are listed in groups by level of evidence, then alphabetically.

#### Recommended for Genotype 3 patients, regardless of cirrhosis status

<table>
<thead>
<tr>
<th>Daclatasvir</th>
<th>Sofosbuvir</th>
<th>Ribavirin</th>
</tr>
</thead>
<tbody>
<tr>
<td>60 mg* once daily for 24 weeks</td>
<td>400 mg once daily for 24 weeks</td>
<td>1000 mg if &lt;75 kg or 1200 mg if ≥75 kg x 24 weeks</td>
</tr>
</tbody>
</table>

**Rating:** Class IIa, Level C  
**Note:** *The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. See the daclatasvir prescribing information for details; the ribavirin daily dose is given in two divided doses.*

#### Recommended for Genotype 3 patients, regardless of cirrhosis status

<table>
<thead>
<tr>
<th>Sofosbuvir-Velpatasvir</th>
<th>Ribavirin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) one tablet once daily for 12 weeks</td>
<td>1000 mg if &lt;75 kg or 1200 mg if ≥75 kg for 12 weeks</td>
</tr>
</tbody>
</table>

**Rating:** Class IIa, Level C  
**Note:** The ribavirin daily dose is given in two divided doses.

Source: AASLD-IDSA. Recommendations for testing, management, and treating hepatitis C. Retreatment of persons in whom prior therapy has failed: DAA-experienced (including NS5A inhibitors), genotype 3 patients with or without compensated cirrhosis. [AASLD-IDSA Hepatitis C Guidance] - Accessed March 10, 2017.